Schering-Plough Rebetron combination therapy
Executive Summary
Schering promoted interferon alfa/ribavirin combination therapy prior to approval, agency maintains in June 12 letter to the company. FDA cites materials disseminated at the Digestive Diseases Week in New Orleans May 16-22 that resembled "a package insert for the combination therapy," letters says. Rebetron was approved by FDA on June 5 ("The Pink Sheet" June 8, p. 15)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth